Pembrolizumab for treatment of a male with primary mediastinal choriocarcinoma: a case report

Abstract

choriocarcinoma. EMA/CO regimen (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine), which is widely used in gestational trophoblastic neoplasia (GTN), is usually given to primary mediastinal choriocarcinoma patients. However, due to drug resistance and heavy tumor burden, the prognosis is poor (3).Programmed cell death 1 ligand 1 (PD-L1) is ubiquitously expressed in choriocarcinoma tumors (4), indicating programmed cell death 1 (PD-1) inhibitor,

Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

“…In a case of primary mediastinal choriocarcinoma, the patient initially achieved partial remission after two cycles of pembrolizumab but developed resistance. Despite attempting a combination treatment of pembrolizumab with chemotherapy, however, the treatment proved unsuccessful due to rapid disease progression ( 48 ). In contrast, a case involving primary neck choriocarcinoma achieved a complete response when treated with a combination of pembrolizumab and chemotherapy ( 49 ).…”

Primary mediastinal choriocarcinoma in an 18‐year‐old male with pulmonary and brain metastasis: A case report

“…Programmed cell death ligand 1 (PD‐L1) inhibitor is a popular alternative therapy in recent years, and PD‐L1 are commonly expressed in choriocarcinoma tumors. 10 Pan and Hou 11 reported a case treated with pembrolizumab after an ineffective induction of EP alone. After two cycles, β‐hCG levels dropped dramatically but soon increased again.…”

Successful treatment of primary mediastinal choriocarcinoma with lung metastasis in a 13‐year‐old male

“…PCC presents insidiously, is easily associated with early pulmonary metastases, is unresponsive to chemotherapy, and has a poor prognosis. 1,2 Here, we report the case of a 13-yearold male with primary mediastinal choriocarcinoma and pulmonary metastases, who was successfully cured by surgery and neoadjuvant chemotherapy.…”

“…is still a significant challenge, and immune checkpoint inhibitors, in combination with other agents, may be a potential new therapeutic option. 2,[10][11][12] In conclusion, we have identified a rare case of PMC with lung involvement and explored its diagnosis and treatment. Treatment of this disease remains a significant challenge, and further investigation in clinical trials is now warranted.…”